Role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity: two cases and review of the literature. (January 2013)

• Record Type: Journal Article
• Authors: Gallucci, Giuseppina; Tartarone, Alfredo; Tocchetti, Carlo Gabriele; Bochicchio, Anna Maria; Coccaro, Mariarosa; Capobianco, Alba; Maurea, Nicola; Improta, Giuseppina; Zupa, Angela; Aieta, Michele
• Is Part Of: Future oncology. Volume 9:Number 1(2013)
• Page Start: 127
• Page End: 133
• Publication Date: 2013-01
• Subjects: preeclampsia -- sunitinib -- TKI-induced cardiotoxicity; Oncology -- Periodicals; 616.99405
• DOI: 10.2217/fon.12.162
• Languages: English
• ISSNs: 1479-6694

Abstract

Sunitinib is a multi-targeted tyrosine kinase inhibitor widely used in clear cell renal carcinoma and in imatinib-resistant gastrointestinal stromal tumors. Sunitinib-associated cardiotoxicity has been recognized and includes hypertension, left ventricular dysfunction and congestive heart failure; nevertheless, few data exist in the literature regarding the role of preeclampsia-related angiogenic factors in sunitinib cardiotoxicity. We report a case of sunitinib-induced severe left ventricular dysfunction that occurred in a hypertensive woman with metastatic renal carcinoma and a history of preeclampsia, and a case of sunitinib-induced preeclampsia-like syndrome in a normotensive patient with an imatinib-resistant gastrointestinal stromal tumor. Our experience confirms that inhibition of angiogenic factors to treat cancer is a novel challenge for the oncologist and requires the cardiologist's support.